GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » 5-Year Yield-on-Cost %

ProPhase Labs (ProPhase Labs) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs 5-Year Yield-on-Cost %?

ProPhase Labs's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for ProPhase Labs's 5-Year Yield-on-Cost % or its related term are showing as below:



PRPH's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.38
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of ProPhase Labs's 5-Year Yield-on-Cost %

For the Diagnostics & Research subindustry, ProPhase Labs's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's 5-Year Yield-on-Cost % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's 5-Year Yield-on-Cost % falls into.



ProPhase Labs 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ProPhase Labs is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

ProPhase Labs  (NAS:PRPH) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


ProPhase Labs 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test

By Value_Insider Value_Insider 12-19-2022

ProPhase Labs Announces Launch of Redesigned Corporate Website

By sperokesalga sperokesalga 04-25-2023